Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

32 та иш

Иш: Reinforcing Adherence to Lipid-lowering Therapy after an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial

  1. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality

    Robin Mathews, William Wang, Lisa A. Kaltenbach +5

    Мақола20182 иқтибос
    ABI

  2. Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design

    Aristi Boulmpou, Αναστάσιος Κάρτας, Ioannis T. Farmakis +9

    Мақола20182 иқтибос
    ABI

  3. Predictors of all‐cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry

    Xavier Rosselló, Héctor Bueno, Stuart Pocock +5

    Мақола20182 иқтибос
    ABI

  4. Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome

    Ioannis T. Farmakis, Stefanos Zafeiropoulos, Areti Pagiantza +9

    Мақола20192 иқтибос
    ABI

  5. Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome

    Stefanos Zafeiropoulos, Ioannis T. Farmakis, Αναστάσιος Κάρτας +15

    Мақола20202 иқтибос
    ABI

  6. Effect of Patient Financial Incentives on Statin Adherence and Lipid Control

    Iwan Barankay, Peter P. Reese, Mary Putt +11

    Мақола20202 иқтибос
    ABI

  7. EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

    Kausik K. Ray, Bart Molemans, W. Marieke Schoonen +28

    Мақола20202 иқтибос
    ABI